Title : Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Pub. Date : 2016 Nov

PMID : 27496136






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Herein, we show that SF1126 (pan PI3K/BRD4 inhibitor) as single agent or in combination with sorafenib inhibited proliferation, cell cycle, apoptosis, and multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway in Hep3B, HepG2, SK-Hep1, and Huh7 HCC cell lines. Sorafenib AKT serine/threonine kinase 1 Homo sapiens